Local treatment of HVJ-E with T cell costimulatory molecule stimulation elicits systemic anti-tumor effects
The tumor-infiltrating lymphocyte (TIL) is a crucial factor in controlling tumor growth. A therapeutic method activating TIL is desired for treating patients with metastatic tumors. Here, we show that treating a local tumor with a combination therapy of UV-irradiated hemagglutinating virus of Japan...
Gespeichert in:
Veröffentlicht in: | Molecular Therapy: Oncology 2024-12, Vol.32 (4), p.200893, Article 200893 |
---|---|
Hauptverfasser: | , , , , , , , , , , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | The tumor-infiltrating lymphocyte (TIL) is a crucial factor in controlling tumor growth. A therapeutic method activating TIL is desired for treating patients with metastatic tumors. Here, we show that treating a local tumor with a combination therapy of UV-irradiated hemagglutinating virus of Japan envelope (HVJ-E) plus agonist antibodies, including OX40, against T cell costimulatory molecules induces systemic anti-tumor effects in a T cell-dependent manner in multiple cancer cell lines. Transcriptome and T cell receptor repertoire analyses revealed that HVJ-E + anti-OX40 antibody treatment activates CD4 and CD8 T cells and promotes T cell trafficking between tumors. These systemic anti-tumor effects required an association between Nkg2d and Nkg2d ligands. Our findings provide insights into how systemic anti-tumor effects are induced and may help the development of therapeutic strategies for eliciting such effects.
[Display omitted]
Nimura and colleagues found that local treatment with combination therapy of UV-irradiated hemagglutinating virus of Japan plus agonist antibodies against T cell costimulatory molecules induces systemic anti-tumor effects in a T cell-dependent manner. This therapy promotes T cell trafficking between tumors and relies on the interaction between Nkg2d and Nkg2d ligands. |
---|---|
ISSN: | 2950-3299 2950-3299 |
DOI: | 10.1016/j.omton.2024.200893 |